Since MYC, p53 and MTOR are known to impact metabolic pathway, therefore, critical evaluation of cellular metabolic pathways, along with protein function, should be investigated to better understand the pathobiology of breast cancer and drug responsiveness. The gene discussed is MYC; the disease is breast carcinoma.